This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias


O'Brien, J. T., Firbank, M. J., Davison, C., Barnett, N., Bamford, C., Donaldson, C., Olsen, K., Herholz, K., Williams, D., Lloyd, J.


Journal Of Nuclear Medicine: Official Publication, Society Of Nuclear Medicine, Volume: 55, No.: 12, Pages.: 1959-1965

Year of Publication



Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and controls (n = 30) underwent (18)F-FDG PET and SPECT in balanced order. The main outcome measure was area under the curve (AUC) of receiver-operating-characteristic analysis of visual scan rating.; Results: Consensus diagnosis with (18)F-FDG PET was superior to SPECT for both dementia vs. no-dementia (AUC = 0.93 vs. 0.72, P = 0.001) and AD vs. DLB (AUC = 0.80 vs. 0.58, P = 0.005) comparisons. The sensitivity and specificity for dementia/no-dementia was 85% and 90%, respectively, for (18)F-FDG PET and 71% and 70%, respectively, for SPECT.; Conclusion: (18)F-FDG PET was significantly superior to blood flow SPECT. We recommend (18)F-FDG PET be performed instead of perfusion SPECT for the differential diagnosis of degenerative dementia if functional imaging is indicated.; © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Bibtex Citation

@article{O_Brien_2014, doi = {10.2967/jnumed.114.143347}, url = {}, year = 2014, month = {nov}, publisher = {Society of Nuclear Medicine}, volume = {55}, number = {12}, pages = {1959--1965}, author = {J. T. O{textquotesingle}Brien and M. J. Firbank and C. Davison and N. Barnett and C. Bamford and C. Donaldson and K. Olsen and K. Herholz and D. Williams and J. Lloyd}, title = {18F-{FDG} {PET} and Perfusion {SPECT} in the Diagnosis of Alzheimer and Lewy Body Dementias}, journal = {Journal of Nuclear Medicine} }


18ffdg pet, aged, aged, 80 and over, alzheimer disease, alzheimer’s disease, brain, dementia with lewy bodies, diagnosis, diagnostic use, female, fluorodeoxyglucose f18, hmpao spect, humans, lewy body disease, male, methods, neuropsychological tests, perfusion, prospective studies, psychology, radionuclide imaging, sensitivity, specificity, technetium tc 99m exametazime

Countries of Study


Types of Dementia

Alzheimer’s Disease, Lewy-Body

Types of Study

Cohort Study

Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Neuroimaging (e.g. MRI, PET, CAT etc.)